UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 15, 2009
RXI PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-33958
|
|
20-8099512 |
|
|
|
|
|
|
| (State or other jurisdiction of
|
|
(Commission
|
|
(I.R.S. Employer |
| of incorporation or organization)
|
|
File Number)
|
|
Identification No.) |
60 Prescott Street, Worcester, MA 01605
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
|
|
|
| Item 5.02 |
|
Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal
Officers; Compensatory Arrangements of Certain Officers. |
(d) On January 15, 2009, the board of directors (the “Board”) of RXi Pharmaceuticals Corporation
(the “Company”) appointed Dr. Rudolph Nisi as a Class I director with a term expiring at the 2011
annual meeting of stockholders of the Company, filling a vacancy that was created when the Board
voted to increase the size of the Board to six members in accordance with the Company’s by-laws.
The appointment of Dr. Nisi as director was not pursuant to any agreement or understanding between
Dr. Nisi and any third party. At the time of his appointment to the Board, Dr. Nisi was not
appointed to serve on any committee of the Board.
A copy of the press release issued in connection with appointment of Dr. Nisi is being filed
as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| |
99.1 |
|
Press Release issued by RXi Pharmaceuticals Corporation on January 22, 2009. |